Price
Frequently asked questions
What is Curevac's market capitalization?
The market capitalization of Curevac is $558.60M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is Curevac's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Curevac is 4.94. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Curevac?
Curevac's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $0.504. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Curevac's stock?
Currently, 9 analysts cover Curevac's stock, with a consensus target price of $8.313. Analyst ratings provide insights into the stock's expected performance.
What is Curevac's revenue over the trailing twelve months?
Over the trailing twelve months, Curevac reported a revenue of $572.78M.
What is the EBITDA for Curevac?
Curevac's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $165.52M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Curevac?
Curevac has a free cash flow of $99.66M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
What is the 5-year beta of Curevac's stock?
The 5-year beta for Curevac is 2.58. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.
How many employees does Curevac have, and what sector and industry does it belong to?
Curevac employs approximately 999 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.
What is the free float of Curevac's shares?
The free float of Curevac is 122.80M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
Market Cap
$558.60M5Y beta
2.58EPS (TTM)
$0.504Free Float
122.80MP/E ratio (TTM)
4.94Revenue (TTM)
$572.78MEBITDA (TTM)
$165.52MFree Cashflow (TTM)
$99.66MPricing
1D span
$2.449$2.577
52W span
$2.215$6.30
Analyst Ratings
The price target is $8.313 and the stock is covered by 9 analysts.
Buy
5
Hold
3
Sell
1
Information
CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve people’s lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.
999
Biotechnology & Drugs
Health Care
Identifier
ISIN
NL0015436031
Primary Ticker
CVAC